Product Details
EYLEA 40MG/ML 0.05ML PFS 1/EA
Manufacturer: REGENERON HEALTHCARE SOLUTIONS
MFG#: 61755-0005-01
NDC: 61755-0005-01
PID: 424312
Additional Information
| Product Name | Eylea 40Mg/Ml 0.05Ml Pfs 1/Ea |
| Active Ingredient | Aflibercept 40 mg/mL |
| Mechanism of Action | Inhibits VEGF-A, VEGF-B, and PlGF to reduce neovascularization and vascular leakage |
| Strength | 40 mg/mL |
| Volume | 0.05 mL (single-use prefilled syringe) |
| Route of Administration | Intravitreal injection |
| Common Side Effects | Conjunctival hemorrhage, eye pain, increased intraocular pressure, blurred vision |
| Serious Adverse Effects | Endophthalmitis, retinal detachment, intraocular inflammation, arterial thromboembolic events |
| Precautions | Use sterile injection technique, monitor patients post-injection for adverse effects |
| Storage Conditions | Refrigerate at 2°C to 8°C (36°F to 46°F), protect from light, do not freeze or shake |
| Packaging | Single-use prefilled syringe (PFS) |
| Uses | Wet age-related macular degeneration (AMD), diabetic macular edema (DME), diabetic retinopathy (DR) |
Description
Eylea 40 mg/mL (0.05 mL prefilled syringe) is an intravitreal anti-vascular endothelial growth factor (VEGF) agent used for the treatment of retinal diseases. It contains aflibercept, a recombinant fusion protein that binds to VEGF-A, VEGF-B, and placental growth factor (PlGF), preventing abnormal blood vessel growth and leakage in the retina. This targeted inhibition reduces macular edema and neovascularization, preserving vision in patients with retinal disorders.
The primary indications for Eylea include neovascular (wet) age-related macular degeneration (AMD), diabetic macular edema (DME), diabetic retinopathy (DR), and macular edema secondary to retinal vein occlusion (RVO). By inhibiting pathological angiogenesis and vascular permeability, Eylea stabilizes or improves visual acuity.
Eylea is administered via intravitreal injection by a qualified healthcare professional under aseptic conditions. Proper patient monitoring is necessary to detect potential complications, including intraocular inflammation, retinal detachment, increased intraocular pressure, and endophthalmitis.
Frequently Asked Questions (FAQs)
The cost of EYLEA 40MG/ML 0.05ML PFS 1/EA is $available for registerd members only
EYLEA 40MG/ML 0.05ML PFS 1/EA is manufactured by REGENERON HEALTHCARE SOLUTIONS.
You can purchase EYLEA 40MG/ML 0.05ML PFS 1/EA on our website at https://supplies.pipelinemedical.com/product/detail/eylea-40mg-ml-0-05ml-pfs-1-ea-424312